Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jul 01, 2006 (Vol. 26, No. 13)

Orphanet

URL:www.orpha.net/consor/cgi-bin/home.php?Lng=GB
  • Functions well at several levels
  • None
The problem of rare diseases and orphan drugs is an important one. Our profit-driven health care system has its faults, as we all recognize, but these are magnified even more if you suffer from a rare disease or disorder for which drug developers aren’t willing to create drugs due to a limited market. There is probably more information on Orphanet than there is for some of the rare diseases described therein. Information is available that is targeted at medical professionals, patients, support groups, industrialists, and the general public. Articles are well-written and easy-to-understand. What more could one ask of a site?
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »